The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRNX | -31.37% | +187.52% | +23.5% | +64% |
| S&P | +16.23% | +94.45% | +14.22% | +139% |
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.03M | 0.0% |
| Gross Profit | $0.07M | 109.6% |
| Gross Margin | 6.98% | 0.0% |
| Market Cap | $2.69B | -23.7% |
| Market Cap / Employee | $6.17M | 0.0% |
| Employees | 437 | 50.7% |
| Net Income | -$115.64M | -56.2% |
| EBITDA | -$128.15M | -55.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $54.23M | -82.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $43.33M | -5.6% |
| Short Term Debt | $6.61M | -11.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -33.24% | 8.8% |
| Return On Invested Capital | -36.93% | 3.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$89.05M | -91.2% |
| Operating Free Cash Flow | -$85.85M | -88.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.88 | 4.96 | 2.35 | 2.15 | -46.65% |
| Price to Sales | 8649.98 | 1937.81 | - | ||
| Price to Tangible Book Value | 4.88 | 4.96 | 2.35 | 2.15 | -46.65% |
| Enterprise Value to EBITDA | -37.72 | -35.92 | -17.19 | -12.10 | -63.46% |
| Return on Equity | -40.3% | -32.0% | -30.8% | -36.9% | -22.49% |
| Total Debt | $52.54M | $51.72M | $50.82M | $49.94M | -6.34% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
